Choroidal neovascularization (CNV) secondary to pathological myopia is an important cause of significant visual impairment in young adults. High myopia is particularly prevalent in Asian population. New scientific contributions have been made to the understanding of high myopia and myopic CNV. Treatment for myopic CNV has previously relied on photodynamic therapy, laser photocoagulation, and submacular surgery. The treatment outcomes from these modalities are, however, controversial. The introduction of antiangiogenic agents including bevacizumab and ranibizumab has brought the treatment of myopic CNV into a new era. The purpose of this review was to provide an overview of the natural history of myopic CNV, the prognostic factors, and the various treatment options including laser photocoagulation and photodynamic therapy, with particular attention on antiangiogenic agents.
From the *Department of Ophthalmology and Visual Sciences, Prince of Wales Hospital, Chinese University of Hong Kong, Hong Kong, People’s Republic of China; and †Dennis Lam and Partners Eye Center, Central Building, Central, Hong Kong, People’s Republic of China.
Received for publication July 5, 2013; accepted September 26, 2013.
The authors have no funding or conflicts of interest to declare.
Reprints: Dr David T.L. Liu, FRCOphth, FRCS, Department of Ophthalmology and Visual Sciences, Prince of Wales Hospital, Chinese University of Hong Kong, 4/F, Hong Kong Eye Hospital, Argyle Street, Kowloon, Hong Kong, People’s Republic of China. E-mail: firstname.lastname@example.org.